MDT perspectives on the limitations of standard of care immunotherapy for non-driver mutation metastatic NSCLC

touchMDT for touchONCOLOGY Listen to key experts from a multidisciplinary team discuss the challenges associated with standard-of-care immunotherapy for metastatic NSCLC without driver mutations, including treatment resistance and toxicity. The multidisciplinary team: Medical Oncologist: Prof. Raffaele Califano, The Christie and Manchester University Hospital, Manchester, UK Oncology Pharmacist: Prof. Lisa Holle, University of Connecticut School of Medicine, Storrs, and UConn Health: Neag Comprehensive Cancer Center, Farmington, CT, USA Pathologist: Prof. Albrecht Stenzinger, University Hospital Heidelberg, Heidelberg, Germany This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/mdt-immunotherapies-for-metastatic-nsclc-without-driver-mutations/